F. Axelrod

发表

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

M. Fischer, J. Lewicki, A. Gurney, 2012, Proceedings of the National Academy of Sciences.

Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control

G. Szot, P. Garg, Qiang Liu, 2021, mAbs.

Expression and ligand binding assays of soluble cytokine receptor-immunoglobulin fusion proteins.

C. Kautzer, K. Becherer, K. Blumeyer, 1998, Protein expression and purification.

Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails

M. Aman, Qiang Liu, Shweta Kailasan, 2020, Antibody therapeutics.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts

A. Gurney, T. Hoey, G. Basso, 2014, Leukemia.

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

Michael F Clarke, Sanjeev Satyal, M. Clarke, 2009, Cell stem cell.

Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity

Jeffrey W. Smith, S. Kridel, F. Axelrod, 2004, Cancer Research.

A Fatty Acid Synthase Blockade Induces Tumor Cell-cycle Arrest by Down-regulating Skp2*

Jeffrey W. Smith, L. Knowles, C. D. Browne, 2004, Journal of Biological Chemistry.

Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries

Cinque S. Soto, Jordan R. Willis, J. Crowe, 2021, mAbs.

Isolation of Erythropoietin Receptor Agonist Peptides Using Evolved Phage Libraries

Steven J Brown, C. Kautzer, K. Becherer, 1998, Biological chemistry.

Maspin alters the carcinoma proteome

Jeffrey W. Smith, J. Yates, L. Florens, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

M. Fischer, J. Lewicki, A. Gurney, 2016, Cancer research.

Discovery and design of G protein-coupled receptor targeting antibodies

C. J. Hutchings, S. Peterson, A. Sato, 2023, Expert opinion on drug discovery.

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism

R. Stafford, S. Peterson, Tom Z. Yuan, 2023, Diabetes.

Abstract 255: Dual targeting of Delta-like ligand 4 (DLL4) and programmed death 1(PD1) inhibits tumor growth and generates enhanced long-term immunological memory

J. Lewicki, A. Gurney, T. Hoey, 2015 .

Antitumor Activity Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Updated

Jeffrey W. Smith, S. Kridel, F. Axelrod, 2004 .

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types

J. Lewicki, A. Gurney, T. Hoey, 2015 .

Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor

Colby A. Souders, Tom Z. Yuan, F. Axelrod, 2024, PloS one.